WHO Sounds Warning Over Severe Shortage of Obesity Medications

Under one in 10 people who could benefit from weight-loss injections like Wegovy can access them, warns the WHO as it releases its initial guidance on the medications.

Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.

Per projections, over two billion could be obese by 2030 unless action is taken.

"The latest guidelines acknowledges that obesity is a chronic disease that can be addressed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the treatments that can aid individuals in losing significant body mass, explains the organization.

GLP-1 Therapy Shortage

Even in the current most favorable outlook, the supply of GLP-1 therapies could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.

The advice urges countries and companies to increase availability, by measures including patent sharing.

Exclusive production rights on the active ingredient – the core component of the drug Wegovy – is due to expire in multiple nations in 2026.

The Way Obesity Injections Work

These medications mimick a natural hormone to delay gastric emptying, curb appetite and increase the sense of being full so people reduce food intake.

Individuals commonly start to lose weight after several weeks of commencing the weekly injections.

Evidence indicates users may put most of the weight back on a year later of discontinuing the treatment, as their typical hunger come back.

Being above a healthy weight increases your chance for contracting health problems, like diabetes, cardiovascular issues, brain attack, and certain cancers.

Obesity affects people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.